Lymphocyte-Rich Classical Hodgkin Lymphoma (LR-cHL) — Specialist Diagnosis & Excellent Outcome Access

Lymphocyte-Rich Classical Hodgkin Lymphoma (LR-cHL) is a rare subtype of classical Hodgkin Lymphoma, accounting for fewer than 5% of cases. It is characterised by a background rich in reactive lymphocytes (normal immune cells) within which the malignant Reed-Sternberg (RS) cells are present but relatively sparse. It carries the best prognosis among all four classical Hodgkin Lymphoma subtypes, typically presents at early stage without B symptoms, and the majority of patients are cured with ABVD-based chemotherapy.

Both LR-cHL and NLPHL have lymphocyte-rich backgrounds, which is why they are sometimes confused. The critical differences are in the tumour cell type and phenotype. In LR-cHL, the malignant cells are classical Reed-Sternberg cells expressing CD30 and CD15 but not CD20. In NLPHL, the malignant cells are called LP ('popcorn') cells and express CD20 strongly but not CD30 or CD15. This distinction has significant treatment implications — NLPHL is more indolent, may be observed at early stage, may be treated with rituximab (anti-CD20), and behaves differently from cHL. Expert haematopathology with full immunohistochemistry is essential to distinguish the two.

LR-cHL is treated with the same chemotherapy framework as other classical Hodgkin Lymphoma subtypes. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 2–6 cycles depending on stage is the standard first-line treatment. Interim PET-CT (iPET2) after 2 cycles guides treatment adaptation — patients with a negative iPET2 can have bleomycin omitted for the remainder of treatment, reducing pulmonary toxicity. Consolidative radiotherapy to involved sites may be added for early-stage unfavourable or bulky disease. The vast majority of LR-cHL patients achieve complete remission with this approach.

Yes — LR-cHL has the most favourable prognosis among all four classical Hodgkin Lymphoma subtypes. This is largely because most patients present at early stage without B symptoms, making them excellent candidates for standard ABVD-based chemotherapy with high cure rates. Even in the small minority of patients who relapse, salvage chemotherapy and autologous stem cell transplantation followed by modern salvage agents (brentuximab vedotin, PD-1 inhibitors) can achieve durable remissions in many patients.

Brentuximab vedotin is an antibody-drug conjugate targeting CD30, which is expressed on Reed-Sternberg cells in all classical Hodgkin Lymphoma subtypes including LR-cHL. It is approved in frontline advanced-stage cHL (combined with AVD), as maintenance after autologous SCT, and for relapsed/refractory cHL. Nivolumab and pembrolizumab are PD-1 checkpoint inhibitors approved for relapsed/refractory cHL, exploiting the near-universal PD-L1 overexpression on RS cells. Both classes of agents are fully applicable to LR-cHL, though the vast majority of LR-cHL patients are cured with first-line ABVD and never require these agents.

Yes, although relapse is less common in LR-cHL than in more aggressive cHL subtypes due to its typically early-stage, chemosensitive presentation. Relapses in LR-cHL may occur late — sometimes many years after initial treatment — and often remain chemosensitive. Salvage chemotherapy followed by autologous stem cell transplantation is the standard approach for relapsed, transplant-eligible patients. PD-1 inhibitors and brentuximab vedotin offer additional options for patients with disease that has progressed through multiple lines of therapy.

Post-treatment follow-up includes end-of-treatment PET-CT to confirm complete metabolic remission, then clinical surveillance every 3–6 months for 2 years, then annually. Routine surveillance CT scanning is no longer recommended in complete remission. Long-term monitoring for treatment late effects is important for all Hodgkin Lymphoma survivors — including cardiovascular disease (from anthracyclines and chest radiotherapy), secondary cancers (particularly thyroid and breast in women after chest radiotherapy), pulmonary function (bleomycin effects), and endocrine function. A survivorship care plan addressing these long-term risks should be provided to all patients.

LR-cHL is quite rare, accounting for fewer than 5% of all Hodgkin Lymphoma cases. The most common subtype is Nodular Sclerosis cHL (approximately 70% of cases), followed by Mixed Cellularity cHL (20–25%), Lymphocyte-Rich cHL (less than 5%), and Lymphocyte-Depleted cHL (less than 1%). Despite its rarity, LR-cHL carries the best prognosis among all four subtypes, and its clinical behaviour is distinct enough to warrant subtype-specific pathological diagnosis, even though treatment follows the same ABVD-based framework.

Yes. CancerFax connects LR-cHL patients with specialist lymphoma haematologists and haematopathologists — providing expert biopsy report review to confirm the LR-cHL diagnosis and exclude NLPHL, PET-CT staging interpretation, second opinion coordination, guidance on ABVD vs A+AVD selection, and access to brentuximab vedotin and PD-1 inhibitor programmes for patients with relapsed or refractory disease. We coordinate with specialist lymphoma centres in India, Germany, South Korea, the UAE, and other countries internationally.